Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies : vimarsana.com

Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Maureen Franco , Dennis Riedl , Kevin Koch , Michael Carruthers , Nasdaq , Twitter , Drug Administration , Instagram , Vp Corporate Communications , Linkedin , Edgewise Therapeutics Inc , European Union , Facebook , European Medicines Agency , Edgewise Therapeutics , Orphan Drug Designations , Orphan Drug , Chief Executive Officer , Orphan Drug Designation , Rare Pediatric Disease Designation , Fast Track , Duchenne Muscular , Chief Financial Officer , Aktien Sie ,